0002001011-24-000028.txt : 20240229
0002001011-24-000028.hdr.sgml : 20240229
20240229185028
ACCESSION NUMBER: 0002001011-24-000028
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240227
FILED AS OF DATE: 20240229
DATE AS OF CHANGE: 20240229
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Espinoza Octavio
CENTRAL INDEX KEY: 0001905248
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33093
FILM NUMBER: 24706125
MAIL ADDRESS:
STREET 1: C/O LIGAND PHARMACEUTICALS INC
STREET 2: 3911 SORRENTO VALLEY BOULEVARD, STE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000886163
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 770160744
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-550-7500
MAIL ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0508
4
2024-02-27
0
0000886163
LIGAND PHARMACEUTICALS INC
LGND
0001905248
Espinoza Octavio
3911 SORRENTO VALLEY, SUITE 110
SAN DIEGO
CA
92121
0
1
0
0
Chief Financial Officer
0
Common Stock
2024-02-27
4
A
0
7208
0.0
A
28631
D
Common Stock
2024-02-28
4
M
0
799
55.75
A
29430
D
Common Stock
2024-02-28
4
M
0
140
57.22
A
29570
D
Common Stock
2024-02-28
4
M
0
325
58.49
A
29895
D
Common Stock
2024-02-28
4
S
0
140
88.46
D
29755
D
Employee Stock Option (right to buy)
55.75
2024-02-28
4
M
0
799
0.0
D
2030-02-13
Common Stock
799
2869
D
Employee Stock Option (right to buy)
57.22
2024-02-28
4
M
0
140
0.0
D
2030-10-01
Common Stock
140
7722
D
Employee Stock Option (right to buy)
58.49
2024-02-28
4
M
0
325
0.0
D
2027-02-24
Common Stock
325
1607
D
Employee Stock Option (right to buy)
89.2
2024-02-27
4
A
0
29272
0.0
A
2034-02-27
Common Stock
29272
29272
D
Represents Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on February 15, 2025; February 15, 2026; and February 15, 2027, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
As per the separation of OmniAb Inc. from the issuer, 2,039 stock options were vested and exercisable as of November 1, 2022, whereas 1,629 options vest in 16 substantially equal monthly installments beginning on November 13, 2022.
As per the separation of OmniAb Inc. from the issuer, 4,096 stock options were vested and exercisable as of November 1, 2022, whereas 3,766 options vest in 23 substantially equal monthly installments beginning on December 1, 2022.
The stock option is fully vested and exercisable.
The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter.
By: /s/ Andrew Reardon, Attorney-in-Fact For: Octavio Espinoza
2024-02-29